Asset Details
Do you wish to reserve the book?
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
Do you wish to request the book?
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
2004
Overview
Among patients with hepatitis B e antigen (HBeAg)–negative chronic hepatitis B, the rates of suppression of hepatitis B virus DNA to below 20,000 copies per milliliter were 43 percent with peginterferon alfa-2a alone, 44 percent with peginterferon alfa-2a plus lamivudine, and 29 percent with lamivudine alone after 48 weeks of treatment and 24 weeks of follow-up; the rates of suppression to below 400 copies per milliliter were 19 percent, 20 percent, and 7 percent, respectively.
Peginterferon alfa-2a was more effective than lamivudine for HBeAg-negative chronic hepatitis B.
Chronic infection with hepatitis B virus (HBV) is a major global health problem, affecting more than 400 million people worldwide.
1
Chronic hepatitis B is associated with serious complications, including liver failure, cirrhosis, and hepatocellular carcinoma. Hepatitis B e antigen (HBeAg)–negative chronic hepatitis B represents a late phase of the infection that is characterized by progressive liver damage
2
,
3
and viral variants with changes in the precore or core promoter region,
4
,
5
which abolish or suppress the expression of HBeAg. Spontaneous, sustained remissions are rare in HBeAg-negative chronic hepatitis B,
6
which has a poor prognosis. HBeAg-negative chronic hepatitis B occurs throughout . . .
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Alanine Transaminase - blood
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ Female
/ Hepatitis B e Antigens - blood
/ Hepatitis B virus - drug effects
/ Hepatitis B virus - genetics
/ Hepatitis B, Chronic - blood
/ Hepatitis B, Chronic - drug therapy
/ Hepatitis B, Chronic - virology
/ Humans
/ Interferon-alpha - adverse effects
/ Interferon-alpha - therapeutic use
/ Lamivudine - adverse effects
/ Lamivudine - therapeutic use
/ Male
/ Polyethylene Glycols - adverse effects
